Warsaw Stock Exchange

Urteste has successfully developed a prototype urine-based diagnostic test for detecting brain tumours

Retrieved on: 
Martedì, Maggio 28, 2024
Lung, Bile, Prognosis, Warsaw Stock Exchange, Patent, Pancreatic cancer, Liver, Urine, FDA, Drug development, Prostate, Cancer, Ovary, Kidney, Brain, Breast, URT, Stomach, IVD, Enzyme, Medical imaging

Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.

Key Points: 
  • Gdańsk, Poland – 28 MAY 2024, Urteste S.A. (Warsaw Stock Exchange: URT) biotechnology company specialising in the development of breakthrough technology to detect cancer from urine samples has developed a prototype IVD test for detecting brain tumours.
  • In the coming months, Urteste plans to start a multi- centre clinical trial in the US and Europe for its flagship project PANURI, a test for pancreatic cancer.
  • Urteste technology is non-invasive, low-cost to produce, has high sensitivity and specificity, and results are available in up to 2 hours.
  • In the coming months, Urteste plans to add the final prototypes to its pipeline and complete the prototype development phase of the tests.

EQS-News: XTPL records all-time high revenues, Strategy execution remains on track

Retrieved on: 
Venerdì, Maggio 3, 2024
Sale, CFO, Investment, Internet of things, E-procurement, PLN, HPM, UPD, Open Market, Apple Thunderbolt Display, Employment, Semiconductor, Electronics, Telecommunications, DPS, Name, Delta, Warsaw Stock Exchange, Growth, Heavy equipment

XTPL records all-time high revenues, Strategy execution remains on track

Key Points: 
  • XTPL records all-time high revenues, Strategy execution remains on track
    The issuer is solely responsible for the content of this announcement.
  • XTPL records all-time high revenues, Strategy execution remains on track
    In 2023, XTPL generated PLN 15.5 million in total revenues and PLN 13.4 million in revenues from the sale of products and services.
  • These proceeds secure the first stage of our investment plans, a key element of our 2023–2026 Strategy.
  • In the XTPL solution, the ultra-high resolution features are coupled with conductive materials characterized by a very high concentration of metallic nanoparticles and high viscosity.

PolTREG identifies promising efficacy biomarker for Type-1 diabetes in patients treated with its Treg therapy in combination with rituximab

Retrieved on: 
Giovedì, Aprile 4, 2024
Rituximab, Multiple sclerosis, ALS, Insulin, Patient, Warsaw Stock Exchange, GMP, PTG, Therapy, Marketing, Autoimmune disease, PD-1, Pharmaceutical industry

This three-arm trial had earlier shown that 50% of PTG-007-treated patients in combination with rituximab were still in remission after 24 months.

Key Points: 
  • This three-arm trial had earlier shown that 50% of PTG-007-treated patients in combination with rituximab were still in remission after 24 months.
  • PolTREG CEO Piotr Trzonkowski, who co-authored the peer-reviewed study, said: “This peer-reviewed scientific publication adds to our growing excitement about the potential of polyclonal Treg therapies.
  • We have treated over 100 patients with our cell therapy at our facility over the last 17 years.
  • Having a biomarker of efficacy, like PD-1+ T-cells, could facilitate doctors’ ability to monitor their patients’ responses to therapy.

Gaming Innovation Group: The Nomination Committee's proposal for election of Board members 2024

Retrieved on: 
Lunedì, Aprile 8, 2024
Annual, Faculty, Platform, Responsibility, Committee, Growth, Bookmaker, Leisure and Gaming, Extel, Warsaw Stock Exchange, Sale, IPO, Emma Capital, Gambling, STS Group, Gig, M&A, Kozminski University, International Center, STS, Corporation

For GiG, and thereby the continued operation of GiG Media, the Nomination Committee has decided to propose that GiG's Annual General Meeting 2024 approves the following proposals regarding the number of board members and election of board members.

Key Points: 
  • For GiG, and thereby the continued operation of GiG Media, the Nomination Committee has decided to propose that GiG's Annual General Meeting 2024 approves the following proposals regarding the number of board members and election of board members.
  • The Nomination Committee proposes that the number of members of the Board of Directors of GiG shall be five.
  • The following new board members shall be elected to join the board:
    Mikael Riese Harstad is to be elected as the Chairman of the Board of Directors.
  • This information is information that Gaming Innovation Group Inc. (GiG) is obliged to make public pursuant to the EU Market Abuse Regulation.

Gaming Innovation Group: The Nomination Committee's proposal for election of Board members 2024

Retrieved on: 
Lunedì, Aprile 8, 2024
Annual, Faculty, Platform, Responsibility, Committee, Growth, Bookmaker, Leisure and Gaming, Extel, Warsaw Stock Exchange, Sale, IPO, Emma Capital, Gambling, STS Group, Gig, M&A, Kozminski University, International Center, STS, Corporation

For GiG, and thereby the continued operation of GiG Media, the Nomination Committee has decided to propose that GiG's Annual General Meeting 2024 approves the following proposals regarding the number of board members and election of board members.

Key Points: 
  • For GiG, and thereby the continued operation of GiG Media, the Nomination Committee has decided to propose that GiG's Annual General Meeting 2024 approves the following proposals regarding the number of board members and election of board members.
  • The Nomination Committee proposes that the number of members of the Board of Directors of GiG shall be five.
  • The following new board members shall be elected to join the board:
    Mikael Riese Harstad is to be elected as the Chairman of the Board of Directors.
  • This information is information that Gaming Innovation Group Inc. (GiG) is obliged to make public pursuant to the EU Market Abuse Regulation.

PolTREG receives CGMP certification to produce cell therapies at its state-of-the-art manufacturing site in Poland

Retrieved on: 
Lunedì, Marzo 11, 2024
ALS, Autoimmune disease, PTG, URPL, Warsaw Stock Exchange, CGMP, Certification, Education minister, Patient, Multiple sclerosis, Medical device, Pharmaceutical industry

PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients, and the first to start receiving revenues from its lead product under a hospital exemption valid in Poland.
  • Its manufacturing facility is one of Europe’s largest and most advanced, boasting over 2,100 sqm of laboratory space, including 15 production lines.
  • PolTREG has the option to substantially expand the facility to accommodate manufacturing of next-generation engineered therapies and cell therapies from future partners.
  • “This certification is an important recognition of PolTREG’s leading capabilities in manufacturing cellular therapies, a highly sophisticated process that requires deep experience to master,” said Prof. Piotr Trzonkowski, Chief Executive Officer of PolTREG.

PolTREG appoints Dan Shelly as Chief Business Development Officer

Retrieved on: 
Mercoledì, Febbraio 21, 2024
PATH, ALS, Autoimmune disease, PTG, Doctor of Philosophy, Prescient Therapeutics, University, MBA, Warsaw Stock Exchange, COVID-19, Therapy, CGMP, Patient, Multiple sclerosis, Biology, Research, Cancer, Pharmaceutical industry

“I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.

Key Points: 
  • “I am elated we were able to attract Dan to help us deliver the promise of Treg cell therapies for a wide range of autoimmune diseases.
  • Dr Shelly is an astute veteran of the life science industry, with a deep understanding of biology and the Treg cell therapies that PolTREG is developing.
  • He was Director of Global Business Development and Strategic Partnerships for the global non-profit PATH, where he was the Co-Lead for the COVID-19 task force.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland.

PolTREG CEO Trzonkowski co-authors peer-reviewed article showing scientific progress in T-reg autoimmune therapy

Retrieved on: 
Martedì, Gennaio 30, 2024
Partnership, WSA, Medical school, Inflammation, Holocene, PTG, Cell, Multiple sclerosis, Immune system, Trial of the century, International Centre, Clinical trial, Therapy, Patient, Institute of technology, White, Frontiers, PPMS, RRMS, Disease, Science, University, Health, ALS, Autoimmune disease, University of Birmingham, Warsaw Stock Exchange, Pharmaceutical industry

PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.

Key Points: 
  • PolTREG was the first company in the world to administer T-reg therapies to patients and the first to start receiving revenues from its lead product.
  • So far, PolTREG has successfully treated 27 patients with PTG-007 commercially under a hospital exemption program in Poland, where the company is completing its own state-of-the-art manufacturing facilities.
  • When found in the body, Treg cells are polyclonal, meaning they can react to a number of different antigenic triggers.
  • PolTREG (Gdańsk, Poland; WSA:PTG) is a global leader in developing autoimmune therapies based on T-regulatory cells (Tregs).

PolTREG receives US Patent Office Notice of Allowance for Treg cell therapy to treat Type-1 Diabetes

Retrieved on: 
Martedì, Gennaio 16, 2024
WSA, Patient, Research, Medical school, Multiple sclerosis, Partnership, Element, Autoimmune disease, Graft-versus-host disease, PTG, Immune system, Cell, PPMS, Hospital, Therapy, Inflammation, RRMS, Patent, White, Warsaw Stock Exchange, Trial of the century, Pharmaceutical industry

The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.

Key Points: 
  • The US allowance constitutes an important addition to the intellectual property portfolio covering PolTREG’s autoimmune therapies.
  • Many of PolTREG’s patent submissions are primary in the field, given that its team performed the first-in-human trials with Treg cell therapies in graft-versus-host disease in 2007-2009.
  • Its lead product, PTG-007, autologous Treg treatment for early-onset Type-1 Diabetes (T1D) is ready to start Phase 2/3 clinical testing, upon partnership.
  • PolTREG also is developing engineered Tregs, including CAR-Tregs, antigen-specific Tregs and TCR-Tregs, all of which are in the preclinical stage.

Equinix Reports Third-Quarter 2023 Results

Retrieved on: 
Mercoledì, Ottobre 25, 2023
Cloud, Press release, International use of the U.S. dollar, Silicon, Canada Customs and Revenue Agency, The Times of India, Public expenditure, EBITDA, Warsaw Stock Exchange, Organization, GAAP, FX, Acquisition, Generative, Global marketing, Research, Customer, Bank statement, Immersion, Interest, Trans-Pacific Partnership, Income tax, Ecosystem, Webcast, IBX, Crux, EQIX, Depreciation, Knowledge production modes, Google AI, AI, XScale, NetApp, Retail, Cryptocurrency, Bookkeeping, Renewable energy, Euro, Gartner, Equinix

Given strong demand signals and the long duration in delivering new capacity, Equinix continues to expand its global footprint.

Key Points: 
  • Given strong demand signals and the long duration in delivering new capacity, Equinix continues to expand its global footprint.
  • Equinix Fabric® saw continued momentum with record port orders, and Equinix Internet Exchange® had another strong quarter with peak traffic reaching nearly 35 terabits per second.
  • Equinix will discuss its quarterly results for the period ended September 30, 2023, along with its future outlook, in its quarterly conference call on Wednesday, October 25, 2023, at 5:30 p.m.
  • Equinix has made available on its website a presentation designed to accompany the discussion of Equinix's results and future outlook, along with certain supplemental financial information and other data.